ConvaTec Group, the £4.7 billion FTSE 100-listed medical products maker that was floated by its private equity backers in October, has named Goldman Sachs and UBS as its joint brokers.

ConvaTec revealed its broking line-up in a statement on January 16, with Goldman Sachs's broking chief Phil Raper named alongside managing director William Smiley, and UBS managing directors Craig Calvert and Christopher Smith.